American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn DSM-5. American Psychiatric Association, Washington

Google Scholar 

Ancill RJ, Carlyle WW, Liang RA, Holliday SG (1991) Agitation in the demented elderly: a role for benzodiazepines? Int Clin Psychopharmacol 6(3):141–146

Google Scholar 

Araki T, Wake R, Miyaoka T et al (2014) The effects of combine treatment of memantine and donepezil on Alzheimer’s disease patients and its relationship with cerebral blood flow in the prefrontal area. Int J Geriatr Psychiatry 29(9):881–889

Google Scholar 

Aupperle PM, Koumaras B, Chen M, Rabinowicz A, Mirski D (2004) Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer’s disease: results of a 52-week open-label study. Curr Med Res Opin 20(10):1605–1612

Google Scholar 

Azhar L, Kusumo RW, Marotta G, Lanctôt KL, Herrmann N (2022) Pharmacological Management of Apathy in dementia. CNS Drugs 36(2):143–165

Google Scholar 

Baldinger P, Lotan A, Frey R, Kasper S, Lerer B, Lanzenberger R (2014) Neurotransmitters and electroconvulsive therapy. J ECT 30(2):116–121

Google Scholar 

Ballard C, Waite J (2006) The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006(1):CD003476. https://doi.org/10.1002/14651858.CD003476.pub2

Ballard C, Creese B, Corbett A, Aarsland D (2011) Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf 10(1):35–43

Google Scholar 

Ballard C, Banister C, Khan Z et al (2018) Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. [published correction appears in Lancet Neurol. 2018 Feb 26]. Lancet Neurol 17(3):213–222

Google Scholar 

Ballard C, Youakim JM, Coate B, Stankovic S (2019) Pimavanserin in Alzheimer's disease psychosis: efficacy in patients with more pronounced psychotic symptoms. J Prev Alzheimers Dis 6(1):27–33

Google Scholar 

Barker AT (2017) Transcranial magnetic stimulation – past, present and future. Brain Stimul 10:540

Google Scholar 

Brooker D (2005) Dementia care mapping: a review of the research literature. The Gerontologist 45(suppl_1):11–18

Google Scholar 

Bruen PD, McGeown WJ, Shanks MF, Venneri A (2008) Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer’s disease. Brain 131(9):2455–2463

Google Scholar 

Carlyle W, Killick L, Ancill R (1991 Jun) ECT: an effective treatment in the screaming demented patient. J Am Geriatr Soc 39(6):637

Google Scholar 

Cassano T, Calcagnini S, Pace L, De Marco F, Romano A, Gaetani S (2017) Cannabinoid receptor 2 signaling in neurodegenerative disorders: from pathogenesis to a promising therapeutic target. Front Neurosci 11:11

Google Scholar 

Chen C, Yeh Y, Chang Y, Huang M (2011) Plasma homocysteine level and apathy in Alzheimer’s disease. J Am Geriatr Soc 59(9):1752–1754

Google Scholar 

Chenoweth L, King MT, Jeon YH et al (2009) Caring for aged dementia care resident study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial. Lancet Neurol 8(4):317–325

Google Scholar 

Cheung G, Stapelberg J (2011) Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials. In: Database of abstracts of reviews of effects (DARE): quality-assessed reviews [Internet]. Centre for Reviews and Dissemination (UK)

Google Scholar 

Chong TTJ, Husain M (2016) The role of dopamine in the pathophysiology and treatment of apathy. In: Progress in brain research, vol 229. Elsevier, pp 389–426

Google Scholar 

Christie D, Shofer J, Millard SP et al (2012) Genetic association between APOE*4 and neuropsychiatric symptoms in patients with probable Alzheimer's disease is dependent on the psychosis phenotype. Behav Brain Funct 8:62. Published 2012 Dec 27

Google Scholar 

Chung EJ, Babulal GM, Monsell SE, Cairns NJ, Roe CM, Morris JC (2015) Clinical features of Alzheimer disease with and without Lewy bodies. JAMA Neurol 72(7):789–796

Google Scholar 

Clarke DE, Ko JY, Kuhl EA, van Reekum R, Salvador R, Marin RS (2011) Are the available apathy measures reliable and valid? A review of the psychometric evidence. J Psychosom Res 70(1):73–97

Google Scholar 

Cooke ML, Moyle W, Shum DHK, Harrison SD, Murfield JE (2010) A randomized controlled trial exploring the effect of music on agitated behaviours and anxiety in older people with dementia. Aging Ment Health 14(8):905–916

Google Scholar 

Corriveau-Lecavalier N, Botha H, Graff-Radford J et al (2024) Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome. Brain Commun 6(4):fcae183

Google Scholar 

Cummings J, Mintzer J, Brodaty H et al (2015a) Agitation in cognitive disorders: international psychogeriatric association provisional consensus clinical and research definition. Int Psychogeriatr 27(1):7–17

Google Scholar 

Cummings JL, Lyketsos CG, Peskind ER et al (2015b) Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA 314(12):1242

Google Scholar 

Cummings J, Pinto LC, Cruz M et al (2020) Criteria for psychosis in major and mild neurocognitive disorders: international psychogeriatric association (IPA) consensus clinical and research definition. Am J Geriatr Psychiatry 28(12):1256–1269

Google Scholar 

De Deyn PP, Carrasco MM, Deberdt W et al (2004) Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 19(2):115–126

Google Scholar 

De Mauleon A, Ismail Z, Rosenberg P et al (2021) Agitation in Alzheimer’s disease: novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria. Alzheimer’s Dementia 17(10):1687–1697

Google Scholar 

DeMichele-Sweet MA, Sweet RA (2014) Genetics of psychosis in Alzheimer disease. Curr Genet Med Rep 2(1):30–38

Google Scholar 

Dettmore D, Kolanowski A, Boustani M (2009) Aggression in persons with dementia: use of nursing theory to guide clinical practice. Geriatr Nurs 30(1):8–17

Google Scholar 

Dolphin H, Dyer AH, McHale C, O’Dowd S, Kennelly SP (2023) An update on apathy in Alzheimer’s disease. Geriatrics 8(4):75

Google Scholar 

Dyer AH, Murphy C, Dolphin H et al (2024) Long-term antipsychotic use, orthostatic hypotension and falls in older adults with Alzheimer's disease. Eur Geriatr Med. Published online January 2 15:527

Google Scholar 

Ehrenberg AJ, Suemoto CK, França Resende EP et al (2018) Neuropathologic correlates of psychiatric symptoms in Alzheimer's disease. J Alzheimers Dis 66(1):115–126

Google Scholar 

Engelborghs S, Vloeberghs E, Le Bastard N et al (2008) The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochem Int 52(6):1052–1060

Google Scholar 

Fahed M, Steffens DC (2021) Apathy: neurobiology, assessment and treatment. Clin Psychopharmacol Neurosci 19(2):181–189

Google Scholar 

Fan P, Qi X, Sweet RA, Wang L (2020) Network systems pharmacology-based mechanism study on the beneficial effects of vitamin D against psychosis in Alzheimer's disease. Sci Rep 10(1):6136. Published 2020 Apr 9

Google Scholar 

Fischer CE, Ismail Z, Schweizer TA (2012) Delusions increase functional impairment in Alzheimer's disease. Dement Geriatr Cogn Disord 33(6):393–399

Google Scholar 

Fischer CE, Ismail Z, Youakim JM et al (2020) Revisiting criteria for psychosis in Alzheimer’s disease and related dementias: toward better phenotypic classification and biomarker research. J Alzheimers Dis 73(3):1143–1156

Google Scholar 

Flanagan RJ, Lally J, Gee S, Lyon R, Every-Palmer S (2020) Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals. Br Med Bull 135(1):73–89

Google Scholar 

Fox C, Crugel M, Maidment I et al (2012) Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double-blind placebo controlled trial. Breitner JCS, ed. PLoS One 7(5):e35185

Google Scholar 

Frederiksen KS, Cooper C, Frisoni GB et al (2020) A European academy of neurology guideline on medical management issues in dementia. Eur J Neurol 27(10):1805–1820

Google Scholar 

Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M et al (2005) Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 43(3):442–449

Google Scholar 

Gatchel JR, Donovan NJ, Locascio JJ et al (2017) Regional 18F-Fluorodeoxyglucose Hypometabolism is associated with higher apathy scores over time in early Alzheimer disease. Am J Geriatr Psychiatry 25(7):683–693

Google Scholar 

Gauthier S, Feldman H, Hecker J et al (2002a) Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr 14(4):389–404

Google Scholar 

Gauthier S, Feldman H, Hecker J et al (2002b) Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer’s disease. Curr Med Res Opin 18(6):347–354

Google Scholar 

Gauthier S, Wirth Y, Möbius HJ (2005) Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the neuropsychiatric inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 20(5):459–464

Google Scholar 

Gill S, Wang M, Mouches P et al (2021) Neural correlates of the impulse dyscontrol domain of mild behavioral impairment. Int J Geriatr Psychiatry 36(9):1398–1406

Google Scholar 

Goris ED, Ansel KN, Schutte DL (2016) Quantitative systematic review of the effects of non-pharmacological interventions on reducing apathy in persons with dementia. J Adv Nurs 72(11):2612–2628

Google Scholar 

Goukasian N, Hwang KS, Romero T et al (2019) Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study. BMJ Open 9(12):e031947

Google Scholar 

Grossberg GT, Kohegyi E, Mergel V et al (2020) Efficacy and safety of Brexpiprazole for the treatment of agitation in Alzheimer’s dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry 28(4):383–400

Google Scholar 

Guimarães HC, Caramelli P, Fialho PPA, de França EP, Afonso MPD, Teixeira AL (2013) Serum levels of soluble TNF-α receptors but not BDNF are associated with apathy symptoms in mild Alzheimer’s disease and amnestic mild cognitive impairment. Dement Neuropsychol 7(3):298–303

Google Scholar 

Halpern R, Seare J, Tong J, Hartry A, Olaoye A, Aigbogun MS (2019) Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementia. Int J Geriatr Psychiatry 34(3):420–431

Google Scholar 

Hattori H, Hattori C, Hokao C, Mizushima K, Mase T (2011) Controlled study on the cognitive and psychological effect of coloring and drawing in mild Alzheimer’s disease patients. Geriatrics Gerontology Int 11(4):431–437

Google Scholar 

Hawranik P, Johnston P, Deatrich J (2008) Therapeutic touch and agitation in individuals with Alzheimer’s disease. West J Nurs Res 30(4):417–434

Google Scholar 

Hermida AP, Tang YL, Glass O, Janjua AU, McDonald WM (2020) Efficacy and safety of ECT for behavioral and psychological symptoms of dementia (BPSD): a retrospective chart review. Am J Geriatr Psychiatry 28(2):157–163

Google Scholar 

Hermush V, Ore L, Stern N et al (2022) Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: a placebo controlled randomized clinical trial. Front Med 9:951889

Google Scholar 

Herrmann N, Rothenburg LS, Black SE et al (2008) Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using Dextroamphetamine challenge. J Clin Psychopharmacol 28(3):296–301

Google Scholar 

Herrmann N, Ruthirakuhan M, Gallagher D et al (2019) Randomized placebo-controlled trial of Nabilone for agitation in Alzheimer’s disease. Am J Geriatr Psychiatry 27(11):1161–1173

Google Scholar 

Hope T, Keene J, Fairburn CG, Jacoby R, McShane R (1999) Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. A longitudinal study. Br J Psychiatry 174:39–44